Avalo Therapeutics, Inc. /
AlmataBio, Inc.
Avalo Therapeutics, Inc. agrees to buy AlmataBio, Inc.
Source for the buyer and target: Avalo Therapeutics, Inc.
For the buyer and target.
“This Milestone Buyout Option Agreement and Amendment to the Agreement and Plan of Merger and Reorganization (this “ Amendment ”) is made as of April 26, 2026 (the “ Amendment Date ”), by and between Avalo Therapeutics, Inc., a Delaware corporation (“ Parent ”) and Patrick Crutcher (the “ Securityholders’ Representative ”), solely in his capacity as the representative agent and attorney-in-fact of the former holders of securities in AlmataBio, Inc., a Delaware corporation (the “ Company ”).”
Published 28 Apr 2026
Open the sourceWhat happened
Avalo Therapeutics, Inc. agreed to acquire AlmataBio, Inc. for $2.25 million, according to a filing dated April 28, 2026. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Avalo Therapeutics, Inc. agrees to buy AlmataBio, Inc.
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Announced
“Avalo Therapeutics, Inc. agrees to buy AlmataBio, Inc. Avalo Therapeutics, Inc. agreed to acquire AlmataBio, Inc. for $2.25 million, according to a filing dated April 28, 2026”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly